Thrombolysis with i.v. recombinant human tissue-type plasminogen activator in patients with bypass graft occlusion: a good adjunctive therapeutic mode (preliminary and case reports)
Related Experiment Videos
F Agresta1, I Michelet, V Boni
1Department of Surgery, Ospedale Civile, Vittorio Veneto, Treviso, Italy.
Background And Methods:
The authors report their experience with thrombolytic therapy in seven cases of graft thrombosis managed successfully with low-dose i.v. rt-TPA. In six patients the cause was an anatomical one and so, after the successful lysis, there was enough time to confirm a correct diagnosis and plan the "right" and "less extensive" surgical procedure, obviating it in one case with a "functional" cause of thrombosis.
Results:
No complication directly attributable to rt-TPA infusion occurred, and no systemic fibrinogenolysis was registered in any cases. Judging from this experience, i.v. rt-TPA appears safe and effective in patients with graft thrombosis, proving to be a good adjunctive therapeutic mode.
Conclusions:
Further studies are needed do delineate more clearly safe indication and the validity of this method.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Clot Retraction and Fibrinolysis
Peripheral Artery Disease V: Postoperative Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins